These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 10086938)

  • 1. Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development.
    Annerén G; Tuvemo T; Carlsson-Skwirut C; Lönnerholm T; Bang P; Sara VR; Gustafsson J
    Arch Dis Child; 1999 Apr; 80(4):334-8. PubMed ID: 10086938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth and somatomedin responses to growth hormone in Down's syndrome.
    Annerén G; Sara VR; Hall K; Tuvemo T
    Arch Dis Child; 1986 Jan; 61(1):48-52. PubMed ID: 2937371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
    Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First two years' response to growth hormone treatment in very young preterm small for gestational age children.
    Garcia RA; Longui CA; Kochi C; Arruda M; Faria CD; Calliari LE; Monte O; Pachi PR; Saenger P
    Horm Res; 2009; 72(5):275-80. PubMed ID: 19844113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant increase of IGF-I concentration and of IGF-I/IGFBP-3 molar ratio in generation test predicts the good response to growth hormone (GH) therapy in children with short stature and normal results of GH stimulating tests.
    Smyczynska J; Hilczer M; Stawerska R; Lewinski A
    Neuro Endocrinol Lett; 2013; 34(3):222-8. PubMed ID: 23685421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of insulin-like binding protein-2 in prepubertal short children and its diagnostic value in the evaluation of growth hormone deficiency.
    van Doorn J; Ringeling AM; Rikken B; van Buul-Offers SC
    Horm Res; 2001; 55(3):147-54. PubMed ID: 11549877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of growth hormone insulin like growth factor-I axis in Down's syndrome.
    Barreca A; Rasore Quartino A; Acutis MS; Ponzani P; Damonte G; Miani E; Balestra V; Giordano G; Minuto F
    J Endocrinol Invest; 1994 Jun; 17(6):431-6. PubMed ID: 7930388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency.
    Rikken B; van Doorn J; Ringeling A; Van den Brande JL; Massa G; Wit JM
    Horm Res; 1998 Sep; 50(3):166-76. PubMed ID: 9762006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose growth hormone treatment of short children born small for gestational age.
    de Zegher F; Maes M; Gargosky SE; Heinrichs C; Du Caju MV; Thiry G; De Schepper J; Craen M; Breysem L; Löfström A; Jönsson P; Bourguignon JP; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1996 May; 81(5):1887-92. PubMed ID: 8626853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined evaluation of IGF-1 and IGFBP-3 as an index of efficacy and safety in growth hormone treated patients.
    Sıklar Z; Öcal G; Berberoğlu M; Bilir P
    J Clin Res Pediatr Endocrinol; 2009; 1(5):240-3. PubMed ID: 21274301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final height and insulin-like growth factor-1 in children with medulloblastoma treated with growth hormone.
    Chae HW; Park YS; Kim DS; Kwon AR; Kim HS; Kim DH
    Childs Nerv Syst; 2013 Oct; 29(10):1859-63. PubMed ID: 23775040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHOX gene variants: growth hormone/insulin-like growth factor-1 status and response to growth hormone treatment.
    Shapiro S; Klein GW; Klein ML; Wallach EJ; Fen Y; Godbold JH; Rapaport R
    Horm Res Paediatr; 2015; 83(1):26-35. PubMed ID: 25659810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
    Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
    J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children.
    Ali A; Hashim R; Khan FA; Sattar A; Ijaz A; Manzoor SM; Younas M
    J Ayub Med Coll Abbottabad; 2009; 21(3):40-5. PubMed ID: 20929010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.